Allogene Therapeutics, Inc. (ALLO)
After hours:
| Previous Close | 2.1100 |
| Open | 2.1200 |
| Bid | 2.1700 x 500 |
| Ask | 2.2400 x 200 |
| Day's Range | 2.0900 - 2.2300 |
| 52 Week Range | 1.9900 - 5.7800 |
| Volume | |
| Avg. Volume | 2,087,335 |
| Market Cap | 463.375M |
| Beta (5Y Monthly) | 0.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.5500 |
| Earnings Date | Nov 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.04 |
GlobeNewswireAllogene Therapeutics Announces Participation in December Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in two upcoming investor conferences in December. The Company is also announcing that the presentation time for the upcoming Jefferies London Healthcare conference on November 20, 2024 has changed. TIME UPDATE
- GlobeNewswire
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence
ALLO-329 Induces Deep, Transient Depletion of CD19+ B Cells and CD70+ T Cells, and Reduction in IgG and IgM without Lymphodepletion in Humanized Murine ModelsProprietary Dagger® Technology Enables ALLO-329 to Overcome Rejection and Expand the Presence of Alloreactive T CellsPresented Data Demonstrates that ALLO-329 Could Be Effective in Treating Autoimmune Diseases with Reduced or No Lymphodepleting ChemotherapyALLO-329 Investigational New Drug (IND) Submission Planned for Q1 2025 SOUTH SAN FRAN
